Genmab: Q4 Earnings Insights

0.00% Pre

Genmab A/S

GMAB

27.96

27.43

0.00%

-1.90% Pre

Genmab (NASDAQ:GMAB) announced its Q4 earnings on Tuesday, February 17, 2026 at 11:00 AM.

Here's a breakdown of the earnings report.

Earnings

Genmab missed estimated earnings by -88.64%, reporting an EPS of $0.05 versus an estimate of $0.44.

Revenue was up $136.44 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.19 which was followed by a 0.62% drop in the share price the next day.

Here's a look at Genmab's past performance:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	0.460	0.360	0.23	0.28
EPS Actual	0.646	0.542	0.31	0.85
Revenue Estimate	4.21B	3.82B	748.58M	885.31M
Revenue Actual	1.02B	925.00M	715.00M	921.56M

To track all earnings releases for Genmab visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.